Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. - Wikidata - awgldk - TriplyDB

Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment.

Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment.

http://www.wikidata.org/entity/Q30481140

about

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.Fragile X syndrome and targeted treatment trials.Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in Fragile X Syndrome Review of targeted treatments in fragile X syndrome The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions Electrocortical changes associated with minocycline treatment in fragile X syndrome.Impaired sensorimotor gating in Fmr1 knock out and Fragile X premutation model mice.Modeling fragile X syndrome in the Fmr1 knockout mouse Fragile X: leading the way for targeted treatments in autism.Auditory processing in fragile x syndrome.Female Mecp2(+/-) mice display robust behavioral deficits on two different genetic backgrounds providing a framework for pre-clinical studies.Prepulse inhibition in patients with fragile X-associated tremor ataxia syndrome.Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.Potential therapeutic interventions for fragile X syndrome Brief report: Sensorimotor gating in idiopathic autism and autism associated with fragile X syndrome Fragile X: a family of disorders.Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.Targeted treatments for fragile X syndrome.Aligning the goals of community-engaged research: why and how academic health centers can successfully engage with communities to improve health Social attention: a possible early indicator of efficacy in autism clinical trials.Outcome measures for clinical trials in fragile X syndrome.Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models.Sensorimotor gating deficits in "two-hit" models of schizophrenia risk factors.Developmental Emergence of Phenotypes in the Auditory Brainstem Nuclei of Fmr1 Knockout Mice.Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice.Prepulse inhibition in larvae

P2860

Q24654933-437D03C1-D944-490C-B92F-0B90FFCCE3B4 Q26865162-221DE93C-C195-45AD-98A8-F0FBE641E07B Q27337360-87EEAB5B-CFB2-4EBA-AC98-D5AAD1E02FB0 Q27337789-184B5DFF-9489-4747-B0CD-4C26521A4771 Q28077180-3680FE52-0371-4837-8B6C-FD8D9C753414 Q29109561-74D5FE52-F185-42C5-AF7D-277C2A09DBEF Q30378165-44CCC15D-D22D-424E-AFA9-57A4E94BF9ED Q30407652-E984FEAD-856E-40E5-949A-C65ABC5C3EDF Q30420595-6FCF05FB-3347-45C1-8BE9-F13D0D65C704 Q30435321-927E408F-17BC-4A1B-8B03-4DC9606D1170 Q30442883-616D7ED7-1AFA-46A2-AD7B-D52D485D7DF4 Q30445073-95B73233-32EB-4795-BD08-55868D015EB9 Q30454136-FD3BC935-7774-4CCD-840D-C7A62F769C60 Q30459497-599BF04D-C767-4A4C-AC1A-F44D09D6EED4 Q30461456-735EB357-1621-46B1-8C42-7819E5B5EE6D Q30473378-AEAAB22F-C3BF-4E1D-9944-BF53C1776727 Q30476901-506E7805-E03C-427F-9DC7-6164C632DFC8 Q30479991-A41953CC-406C-4A2E-9EC6-EA4FB5B7C458 Q30855390-B03B76B6-1930-40E6-8E58-2FFC2AED236B Q33650170-C8FBD9BA-26B6-4E82-8BF7-69637497A270 Q33785978-5F4081B4-1FF7-43C8-9AE3-FA2690C51D5B Q34487591-DEBDDF1D-5B12-469F-AEFC-57151A525930 Q35614072-D8376AD0-3ED5-46F3-9B22-CE75894D04D5 Q35680726-D6C2AB14-2381-480B-BC82-69F40912D3BE Q35799237-89E342B0-5D14-4706-8144-5F52A95B8184 Q36217717-E5626A2A-02D7-4595-927C-A86990E54230 Q37199656-A945FABD-C0B6-4D31-B962-9E621DA1A96B Q37564195-B6140611-9AE0-43BF-B956-FFC3B8A37367 Q46096598-30AA4990-C090-4403-AABF-BD48A60CB42D Q47164654-643B01DE-1494-460E-B582-30B6CDB066FD Q48481845-B837AA18-FA57-454D-ABAB-57AFDB947796 Q58736455-FE691B1F-FA4E-4FFE-B577-91D212BB3F5F

P2860

Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment.

http://www.wikidata.org/entity/Q30481140

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Prepulse inhibition in fragile ...... nd implications for treatment.

@ast

Prepulse inhibition in fragile ...... nd implications for treatment.

@en

type

label

Prepulse inhibition in fragile ...... nd implications for treatment.

@ast

Prepulse inhibition in fragile ...... nd implications for treatment.

@en

prefLabel

Prepulse inhibition in fragile ...... nd implications for treatment.

@ast

Prepulse inhibition in fragile ...... nd implications for treatment.

@en

P1433

Q30481140-7A90624D-B70E-4430-93B1-B5E9C391E7D2

P1476

Q30481140-15F66D1E-F5CC-4953-A526-3C55E9A3B188

P2093

Q30481140-18CFB4AB-172A-4A2B-BA8D-E6B5607B3065

Q30481140-1CE1D558-3AF4-484F-A7CD-F208E0CDA437

Q30481140-20787DBF-7B6B-4A74-83A6-36B00FC94B70

Q30481140-328B8594-9628-4F1D-B845-0BD3EA3790CC

Q30481140-4F5147BC-63F2-408B-88D8-BCB96B6105EC

Q30481140-5C6E5E12-4A2D-421C-A656-12ED22F09022

Q30481140-688B36FF-5143-4FE6-9A67-69E1B6E3FA79

Q30481140-91BCDE19-C96A-4A02-9F92-0551D7355808

Q30481140-CEB7FAE2-D0B6-445C-95A2-AF00215D6F1C

Q30481140-D50D04B0-7CD3-4790-9200-6596617205DA

P2860

Q30481140-02048678-AAE6-4C0F-AFCD-C8E22549ED24

Q30481140-02BEC5FC-B62A-4BCF-856B-08084BEA7589

Q30481140-0FB8CA51-0839-4731-BF3E-66272DD97EBD

Q30481140-199760FC-2CE5-4D05-AF26-B654837F83AE

Q30481140-1C1D5A58-8E9C-4611-91EA-1AEBA86BB22A

Q30481140-1DA7EDBB-D500-4FB3-B287-689796879398

Q30481140-253CFAF5-92FC-4D68-AFA2-15E2F0142FE3

Q30481140-25E010F4-6611-4A75-8E1C-28E3727EE253

Q30481140-263B2971-2B48-48E3-9680-11ED4967007F

Q30481140-2863AA1E-B31E-4E2F-B398-4A997DCD217D

P304

Q30481140-FE2D6016-4653-45A9-96B3-562399A1F4BB

P31

Q30481140-D377717A-6A35-4D4C-B00F-FF8983B054B2

P356

Q30481140-2BB85896-CDE7-4A99-957F-EF775E8978CE

P433

Q30481140-FA7EA8E8-6DA4-4D6A-90BF-48E9C9A232FE

P478

Q30481140-9115B0B5-AA99-49C2-AAF5-72663ED7340A

P577

Q30481140-3B0333BE-54F5-4D40-8D09-19A924B38A71

P5875

Q30481140-3A6B8CF5-C7AB-4C3C-AF9C-8D0E44007673

P698

Q30481140-4F7D6C20-8372-480C-B758-A83A94AB2C0D

P932

Q30481140-5E5C8748-9541-4EA8-9F7B-C0400B3C0E30

P356

P1433

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

P1476

Prepulse inhibition in fragile ...... nd implications for treatment.

@en

P2093

Aaron Campbell

http://www.w3.org/2001/XMLSchema#string

Crystal Hervey

http://www.w3.org/2001/XMLSchema#string

David Hessl

http://www.w3.org/2001/XMLSchema#string

Edward M Ornitz

http://www.w3.org/2001/XMLSchema#string

Elizabeth Berry-Kravis

http://www.w3.org/2001/XMLSchema#string

Elizabeth Chruscinski

http://www.w3.org/2001/XMLSchema#string

James M Long

http://www.w3.org/2001/XMLSchema#string

Jennifer Yuhas

http://www.w3.org/2001/XMLSchema#string

Lisa Cordeiro

http://www.w3.org/2001/XMLSchema#string

Randi J Hagerman

http://www.w3.org/2001/XMLSchema#string

P2860

Differential expression of FMR1, FXR1 and FXR2 proteins in human brain and testis

Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease.

Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits

Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies

The mGluR theory of fragile X mental retardation

The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia.

Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice.

The relationship between sensorimotor gating and clinical improvement in acutely ill schizophrenia patients.

Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia

The behavioral neurogenetics of fragile X syndrome: analyzing gene-brain-behavior relationships in child developmental psychopathologies.

P304

545-553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJMG.B.30858

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

150B

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23251769

http://www.w3.org/2001/XMLSchema#string

P698

18785205

http://www.w3.org/2001/XMLSchema#string

P932

2693303

http://www.w3.org/2001/XMLSchema#string